An innovative drug, tafamidis, will be available from 13 May for NHS patients in England with the rare heart condition transthyretin amyloidosis cardiomyopathy (ATTR-CM).
Patients with ATTR-CM have a build-up of protein in the heart which often results in heart failure and can be fatal. Symptoms include shortness of breath, palpitations and abnormal heart rhythms, fatigue, fainting, and chest pain. Previous treatment …